araag2/HINT huggingface dataset:
Clinical trial NCT00402103 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: aliskiren, amlodipine, hydrochlorothiazide
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Outpatients 18 years of age or older

          -  Male or female patients are eligible

          -  For newly diagnosed/untreated patients with essential hypertension defined as msDBP ≥
             90 and < 110 mmHg at Visit 1 and Visit 4

          -  For previously treated patients with essential hypertension defined as msDBP ≥ 90 and
             < 110 mmHg after 2 to 4 weeks of washout (Visit 4)

        Exclusion Criteria:

          -  Severe hypertension

          -  History or evidence of a secondary form of hypertension

          -  History of Hypertensive encephalopathy or cerebrovascular accident.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01617434 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: liraglutide, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with type 2 diabetes for at least 180 days prior to screening and treated
             with stable basal insulin analogue dose of minimum 20 U/day with or without stable
             metformin equal to or above 1500 mg/day for at least 8 weeks prior to screening
             (defined as insulin adjustments less than 10% during the past 8 weeks as assessed by
             the investigator)

          -  HbA1c (glycosylated haemoglobin A1c) 7.0-10.0% (both inclusive)

          -  Body mass index (BMI) 20-45 kg/m^2 (both inclusive)

        Exclusion Criteria:

          -  Female of child-bearing potential who is pregnant, breast-feeding or intending to
             become pregnant

          -  Recurrent severe hypoglycaemic episodes or hypoglycaemic unawareness

          -  Treatment with glucose-lowering agent(s) other than stated in the inclusion criteria
             in a period of 12 weeks prior to screening

          -  Impaired liver or renal function

          -  Uncontrolled treated or untreated hypertension (systolic blood pressure (SBP) equal to
             or above 180 mmHg and/or diastolic blood pressure (DBP) equal to or above 100 mmHg)

          -  Any clinically significant disorder, except for conditions associated with type 2
             diabetes history which in the investigator's opinion could interfere with results of
             the trial

          -  Known or suspected abuse of alcohol or narcotics
Clinical trial NCT00220337 (phase 3, status: completed)
Conditions: painful diabetic neuropathy
ICD codes: G58.0, G61.1, A52.15, G60.3, G61.82, H46.2, H46.3
Drugs: lacosamide
SMILES: COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Painful diabetic neuropathy

        Exclusion Criteria:

          -  no clinically relevant liver enzyme abnormalities and impaired renal function, no
             cardiac abnormalities, no pregnant or nursing females
Clinical trial NCT00350467 (phase 3, status: completed)
Conditions: acute schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: er oros paliperidone and olanzapine
SMILES: CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
Eligibility criteria:

        Inclusion Criteria:

          -  Patients (or their legally acceptable representatives) must have signed an informed
             consent document indicating that they understand the purpose of and procedures
             required for the study and are willing to participate in the study

          -  DSM-IV diagnosis of schizophrenia (295.10, 295.20, 295.30, 295.60, 295.90) at entry

          -  Total PANSS score at screening and baseline between 60 and 120, inclusive

          -  Female patients must be postmenopausal for at least 1 year, surgically sterile, or
             practicing an effective method of birth control (e.g., prescription oral
             contraceptives, contraceptive injections, intrauterine device, double-barrier method,
             contraceptive patch) before entry (and agree to continue that method throughout the
             study) - abstinence is not an acceptable method

          -  have a negative urine b hCG pregnancy test at screening

          -  Capable of self-administering study drug, or has consistent help and support available
             throughout the study to do this

        Exclusion Criteria:

          -  A DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) Axis I diagnosis
             other than schizophrenia

          -  Inability to swallow the study drug whole with the aid of water (participants may not
             chew, divide, dissolve, or crush the study drug, as this may affect the release
             profile)

          -  Previous history of a lack of response to any antipsychotic (lack of response defined
             as subject having had least twice a documented medical history of no clinical response
             despite adequate doses and durations of treatment, or the inability to tolerate
             effective doses)

          -  Significant risk of suicidal or violent behavior

          -  Injection of a depot antipsychotic within 120 days before screening, or use of
             paliperidone palmitate within 10 months before screening

          -  Use of monoamine oxidase inhibitors within 4 weeks before screening

          -  Use of antidepressants other than monoamine oxidase inhibitors or mood stabilizers
             (e.g., antiepileptics, lithium) within 2 weeks before screening

          -  Received electroconvulsive therapy within 3 months before screening
Clinical trial NCT01395524 (phase 3, status: completed)
Conditions: opioid-induced constipation (oic)
ICD codes: F11.14, F11.181, F11.182, F11.188, F11.19, F11.24, F11.281
Drugs: nktr-118, nktr-118, placebo
SMILES: COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5, COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must have completed the 12-week study D3820C00004 through Visit 8.

          -  Provision of written informed consent prior to any study-specific procedures.

          -  Men and women who were between the ages of >18 and <85 years at the time of the
             screening visit for study D3820C00004.

          -  Continuing to receive a stable maintenance opioid regimen consisting of a total daily
             dose of 30 mg to 1000 mg of oral morphine, or equianalgesic amount(s) of 1 or more
             other opioid therapies.

          -  Willingness to continue abstinence from all laxatives and other bowel regimens
             including prune juice and herbal products throughout this additional 12-week treatment
             period, and to use only bisacodyl as rescue medication if a bowel movement (BM) has
             not occurred within at least 72 hours of the last recorded BM.

        Exclusion Criteria:

          -  Patients receiving opioid regimen for treatment of pain related to cancer.

          -  History of cancer within 5 years from the screening visit of study D3820C00004 with
             the exception of basal cell cancer and squamous cell skin cancer.

          -  Medical conditions and treatments associated with diarrhea, intermittent loose stools,
             or constipation.

          -  Other issues related to the gastrointestinal tract that could impose risk to the
             patient.

          -  Pregnancy or lactation.
Clinical trial NCT00125346 (phase 3, status: terminated)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: tobramycin inhalation powder
SMILES: CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC
Reason stopped: 
    per data monitoring committee recommendation
  
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of cystic fibrosis patients with Pseudomonas aeruginosa infection.

          -  Male and female subjects between 6 and 21 years of age at the time of screening.

          -  FEV1 at screening must be between 25% and 80% of normal predicted values.

        Exclusion Criteria:

          -  Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.
Clinical trial NCT00840294 (phase 3, status: terminated)
Conditions: elevated prostate specific antigen
ICD codes: R97.20
Drugs: ciprofloxacin
SMILES: OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O
Reason stopped: 
    combination of futility analysis and poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Men 18 yrs. or older

          -  An elevated PSA (>2.5 ng/ml) and normal digital rectal exam

          -  Have elected to proceed with a diagnostic 12-core prostate biopsy

        Exclusion Criteria:

          -  Previous prostate biopsy

          -  History of prostate cancer

          -  Urinary tract infections or prostatitis within one year of study entry

          -  antibiotic use within one month prior to PSA level

          -  pyuria or bacteruria on urinalysis

          -  allergy to fluoroquinolones
Clinical trial NCT00124072 (phase 3, status: completed)
Conditions: cardiovascular disease
ICD codes: A52.00, A52.09, A50.54, Z01.810, Q87.418, Z13.6, R94.30
Drugs: simvastatin 20 mg daily, simvastatin 80 mg daily, placebo
SMILES: CC1=CC(O)=CC(C)=C1Cl, CC1=CC(O)=CC(C)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Prior myocardial infarction

          -  Statin therapy indicated

          -  No clear indication for folic acid

        Exclusion Criteria:

          -  No clear contraindication to study treatments

          -  Screening plasma total cholesterol <3.5 mmol/l in patient already on statin therapy,
             or <4.5 mmol/l in patient not on statin therapy

          -  Chronic liver disease

          -  Severe renal disease or evidence of renal impairment

          -  Inflammatory muscle disease

          -  Concurrent treatment with fibrates or high-dose niacin

          -  Concurrent treatment with cyclosporin (or condition likely to result in organ
             transplantation and the need for cyclosporin), nefazodone, methotrexate, systemic
             azole antifungal or systemic macrolide antibiotics

          -  Child bearing potential

          -  No other predominant medical problem (other than coronary heart disease [CHD]) which
             might limit compliance with 5 years of study treatment
Clinical trial NCT00191152 (phase 3, status: completed)
Conditions: breast cancer, breast neoplasms, cancer of the breast
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: gemcitabine, docetaxel, capecitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic or cytologic confirmation of breast cancer with locally advanced and/or
             metastatic disease

          -  Patients may have received prior neo-adjuvant or adjuvant taxane regimen as long as it
             has been greater than or equal to 6 months since completion of the regimen

          -  Patients may have had 0-1, but no more than one prior course of chemotherapy for
             metastatic disease

          -  Patients must have either measurable or non-measurable (evaluable) disease

          -  Prior radiation therapy allowed of less than 25% of the bone marrow

        Exclusion Criteria:

          -  Second primary malignancy (except in situ carcinoma of the cervix or adequately
             treated nonmelanomatous carcinoma of the skin or other malignancy treated at least 5
             years previously with no evidence of recurrence)

          -  Parenchymal or leptomeningeal brain metastases

          -  Peripheral neuropathy greater than or equal to grade 2

          -  Prior treatment with gemcitabine and capecitabine will not be allowed. Prior treatment
             with a taxane in the metastatic setting will not be allowed. Prior taxane therapy in
             the neo-adjuvant or adjuvant setting is allowed if completion of therapy greater than
             or equal to 6 months prior to enrollment.

          -  Active cardiac disease not controlled by therapy and/or myocardial infarction within
             the preceding 6 months.

          -  Concomitant Herceptin is not allowed
Clinical trial NCT01405560 (phase 3, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: vaniprevir, ribavirin
SMILES: [H][C@@]1(CC)C[C@]1(N=C(O)[C@]1([H])C[C@]2([H])CN1C(=O)[C@@]([H])(N=C(O)OCC(C)(C)CCCCC1=C3CN(CC3=CC=C1)C(=O)O2)C(C)(C)C)C(O)=NS(=O)(=O)C1CC1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion criteria:

          -  Japanese participant diagnosed with compensated CHC GT 1

          -  Absence of ascites, bleeding esophageal varices, hepatic encephalopathy, or other
             signs or symptoms of advanced liver disease

          -  Has received and tolerated treatment with IFN-based therapy (IFN α, IFN β, or peg-IFN)
             with or without use of ribavirin, but failed to respond to the prior treatment
             (partial responder or null responder)

          -  No evidence of cirrhosis

        Exclusion criteria:

          -  Co-infection with human immunodeficiency virus (HIV)

          -  Positive hepatitis B surface antigen or other evidence of active hepatitis B infection

          -  Any other condition that is contraindicated or for which caution is required for
             treatment with peg-IFN or RBV

          -  Any condition or pre-study laboratory abnormality, or history of any illness, that, in
             the opinion of the investigator, might confound the results of the study or pose
             additional risk in administering the study drugs, peg-IFN and RBV, to the participant
Clinical trial NCT00475514 (phase 3, status: completed)
Conditions: migraine
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: frovatriptan 2.5mg qd, frovatriptan 2.5 mg bid, placebo
SMILES: CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O, CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Pre-menopausal females diagnosed as suffering from MRM aged 15 years and over, that
             fit the criteria for 'difficult to treat'
Clinical trial NCT00541489 (phase 3, status: completed)
Conditions: osteoarthritis, osteoarthritis, hip
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019, M16.9, M16.0, M16.10, M16.11, M16.12, M16.30, M16.31
Drugs: naproxcinod, naproxen, placebo
SMILES: COC1=CC2=CC=C(C=C2C=C1)[C@H](C)C(=O)OCCCCO[N+]([O-])=O, COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women (40 or older) with a diagnosis of primary OA of the hip

          -  Must be a current chronic user of NSAIDS or acetaminophen

          -  Must discontinue all analgesic therapy at Screening

        Exclusion Criteria:

          -  Uncontrolled Hypertension or Diabetes

          -  Hepatic or renal impairment

          -  Current or expected use of anticoagulant

          -  Clinically relevant abnormal ECG

          -  A history of alcohol or drug abuse

          -  Diagnosis of gastric or duodenal ulceration and/or history of significant
             gastro-duodenal bleeding, within the last 6 months

          -  Current medical disease, including arthritic, that could confound or interfere with
             the evaluation of efficacy

          -  Candidates for imminent joint replacement

          -  Participation within 30 days prior to screening in another investigational study
Clinical trial NCT00168363 (phase 3, status: completed)
Conditions: glaucoma, ocular hypertension
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821, H40.053, H40.051, H40.052, H40.059
Drugs: brimonidine
SMILES: BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
Eligibility criteria:

        Inclusion Criteria:

          -  ocular hypertension or glaucoma in both eyes

          -  currently treated with brimonidine

          -  requires IOP-lowering therapy in both eyes

        Exclusion Criteria:

          -  uncontrolled systemic disease

          -  known allergy or sensitivity to brimonidine
Clinical trial NCT00440414 (phase 3, status: completed)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: erlotinib (tarceva), pemetrexed (alimta)
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically- or cytologically- confirmed Non-Small-Cell Lung Cancer adenocarcinoma

          -  Stage IIIB/IV

          -  Failure to prior chemotherapy

          -  Presence of two-dimensional measurable disease. The measurable disease should not have
             been irradiated

          -  Absence or irradiated and stable central nervous system metastatic disease.

          -  Life expectancy of more than 3 months

          -  Tissue sample desired for genomic study

          -  Age ≥ 18 years

          -  Performance status (WHO) < 3

          -  For patients > 65 years old: "non-frail" according to comprehensive geriatric
             assessment

          -  Adequate bone marrow function (absolute neutrophil count > 1000/mm^3, platelet count >
             100000/mm^3, hemoglobin > 9gr/mm^3)

          -  Adequate liver (bilirubin < 1.5 times upper limit of normal and SGOT/SGPT < 2 times
             upper limit of normal) and renal function (creatinine < 2mg/dl)

          -  Presence of a reliable care giver for patients > 65 years old

          -  Informed consent.

        Exclusion Criteria:

          -  Psychiatric illness or social situation that would preclude study compliance

          -  Other concurrent uncontrolled illness

          -  Other invasive malignancy within the past 5 years except nonmelanoma skin cancer
Clinical trial NCT00436839 (phase 3, status: completed)
Conditions: prostatic neoplasms
ICD codes: B38.81, N42.31, Z87.430, N40.0, N40.1
Drugs: docetaxel, mitoxantrone, prednisone
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically proven prostate adenocarcinoma

          -  Androgen independent prostate Cancer S/P orchiectomy and/or LHRH agonist Testosterone
             < 50 ng/dl (ie 1.735 nmol/l)

          -  Documented progressive disease

          -  Patients should have achieved stable analgesia for 7 days

          -  Karnofsky Performance Status ≥ 70

          -  No prior treatment with cytotoxic agent (except estramustine)

          -  Normal cardiac function must be confirmed by Left ventricular ejection fraction

          -  Adequate organ function:

               1. Hematology:

                    -  Neutrophils > 1.5 x 10^9/L

                    -  Hemoglobin > 10 g/dl. Erythropoietin use is allowed, but red blood cell
                       transfusion to upgrade the hemoglobin level is not allowed

                    -  Platelets > 100 x 10^9/L

               2. Hepatic function:

                    -  Total bilirubin < the upper-normal limit of the institution.

                    -  Alanine aminotransferase and Aspartate transaminase < 1.5 times the
                       upper-normal limit of the institution.

               3. Renal function:

                    -  Creatinine < 1.5 times the upper normal limit (ie National Cancer
                       Institution grade < 1)

          -  No brain or leptomeningeal metastases

        Exclusion Criteria:

          -  Prior radiotherapy to >25% of bone marrow (whole pelvic irradiation is not allowed)

          -  prior cytotoxic chemotherapy, except monotherapy with estramustine

          -  prior isotope therapy

          -  history of another cancer within the preceding five year

          -  symptomatic peripheral neuropathy grade ≥ 2

          -  other serious illness or medical condition:

               1. Congestive heart failure even if controlled. Previous history of myocardial
                  infarction or angina pectoris within 1 year from study entry, uncontrolled
                  hypertension or uncontrolled arrhythmias.

               2. Active uncontrolled infection

               3. Peptic ulcer, unstable diabetes mellitus or other contraindications for the use
                  of corticosteroids.

               4. Auto-immune disease (lupus, sclerodermia, rheumatoid polyarthritis)

          -  treatment with any other anti-cancer therapy

          -  treatment with bisphosphonates

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.